العلاجات والجراحات التخصصية

Cardiac

CABG (bypass), valve repair/replacement, and angioplasty/stenting. A flagship specialty for Medanta, Fortis Escorts Heart Institute, and Max — a strong anchor treatment.

Cosmetic

Rhinoplasty, liposuction, breast augmentation/reduction, hair transplant, facelifts. A major draw for Gulf and African patients; a good early trust-building category.

Dental

Implants, full-mouth rehabilitation, cosmetic dentistry, and root canals. A popular, quick-trip category, often combined with tourism.

Oncology

Surgical oncology, chemotherapy, radiation therapy, and targeted/immunotherapy. High emotional-support and coordination need — a good differentiator for strong patient-coordinator service.

Orthopedic

Total knee replacement, hip replacement/resurfacing, and joint revision. High-volume, high-satisfaction category, especially for older patients from Gulf/CIS countries.

Wellness

Traditional Ayurvedic therapy, panchakarma, and wellness/rejuvenation retreats. Best offered as a pre/post-treatment add-on for NCR patients rather than a standalone draw.

Bariatric

Gastric bypass, sleeve gastrectomy, and gastric banding. Strong cost advantage and growing global demand.

Fertility

IVF, ICSI, and egg/sperm donation. Large draw from Africa and the Middle East. Note: commercial surrogacy for foreigners is restricted under current Indian law.

Neurosurgery

Brain tumor surgery, spinal fusion, minimally invasive spine procedures, and deep brain stimulation.

Ophthalmology

LASIK/refractive surgery, cataract surgery with premium IOLs, and retina procedures. Low cost, high volume, short recovery — a good starter procedure to build source-market trust.

Transplant

Living-donor and deceased-donor liver/kidney transplants, and bone marrow/stem cell transplants for blood cancers. Legally sensitive — subject to India's Transplantation of Human Organs Act. Deferred beyond Phase 1.

Regenerative

Experimental/emerging regenerative treatments for orthopedic, neurological, and autoimmune conditions. Regulatory oversight is still evolving — vet any partner carefully; higher reputational/liability risk.